Genasys Inc. Files 8-K: Material Agreement, Officer Changes

TL;DR

Genasys (GNSS) filed an 8-K detailing a new material agreement and executive compensation changes.

AI Summary

Genasys Inc. announced on January 14, 2025, a material definitive agreement and changes in its board and officer compensation. The company also disclosed information related to Regulation FD and filed financial statements and exhibits. This filing follows a name change from LRAD Corp in 2010 and American Technology Corp. in 1994.

Why It Matters

This 8-K filing indicates significant corporate actions, including a new material agreement and potential changes in executive compensation, which could impact the company's strategic direction and financial performance.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and changes in officers/compensation, which can introduce uncertainty and potential shifts in company strategy.

Key Players & Entities

• Genasys Inc. (company) — Registrant
• LRAD Corp (company) — Former company name
• AMERICAN TECHNOLOGY CORP /DE/ (company) — Former company name
• January 14, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.00001 — nge on which registered Common stock, $0.00001 par value per share GNSS The Nasdaq
• $30,000 — ve (a) an annual cash retainer equal to $30,000, which is paid in equal quarterly insta

Filing Documents

• gnss-20250114.htm (8-K) — 50KB
• gnss-ex10_1.htm (EX-10.1) — 131KB
• gnss-ex99_1.htm (EX-99.1) — 15KB
• img147471742_0.jpg (GRAPHIC) — 83KB
• 0000950170-25-006030.txt ( ) — 446KB
• gnss-20250114.xsd (EX-101.SCH) — 23KB
• gnss-20250114_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On January 14, 2025, Genasys Inc., a Delaware corporation (the "Company"), entered into a Cooperation Agreement (the "Cooperation Agreement") with Nicoya Capital LLC, Nicoya Fund LLC and Nicoya Genasys-SPV LLC (the "Investor Parties"). Pursuant to the Cooperation Agreement, the Company agreed to, among other things, increase the number of members of the Board of Directors of the Company (the "Board") from six to seven members and appoint R. Rimmy Malhotra to the Board and to the Audit Committee of the Board, each effective January 15, 2025. Pursuant to the Cooperation Agreement, the Investor Parties agreed to abide by certain standstill restrictions and voting commitments, subject to certain limited exceptions, during the term of the Cooperation Agreement. The Cooperation Agreement also includes procedures regarding the replacement of Mr. Malhotra and a mutual non-disparagement provision. The Cooperation Agreement will remain effective until the earlier of (a) the date that is 15 calendar days prior to the deadline set forth in the Company's Restated Bylaws for the stockholder nomination of director candidates for election to the Board at the Company's 2026 annual meeting of stockholders, (b) any material breach of the Cooperation Agreement by the Investor Parties, Mr. Malhotra or any director appointed to replace Mr. Malhotra not being cured within five business days' written notice by the Company to the Investor Parties; provided that the Company is not then in material breach of the Cooperation Agreement, or (c) five days after the resignation of Mr. Malhotra from the Board and delivery by the Investor Parties to the Company of a written representation that the Investor Parties irrevocably waive their right to appoint a director to replace Mr. Malhotra. The Cooperation Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The description of the Cooperation Agreement herein

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 16, 2025, the Company issued a press release announcing its appointment of Mr. Malhotra to the Board and to the Audit Committee of the Board pursuant to the Cooperation Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference to this Item 7.01 herein. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Cooperation Agreement, dated as of January 14, 2025, among Genasys Inc. and Nicoya Capital LLC, Nicoya Fund LLC and Nicoya Genasys-SPV LLC. 99.1 Press release of Genasys Inc. dated January 16, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Genasys Inc. Date: January 16, 2025 By: /s/ RICHARD S. DANFORTH Richard S. Danforth Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR